Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies : Episode 8
Opinion
Video
PIK3CA Mutations and Delivering PI3K Inhibitors
In their discussion, the key opinion leaders explore the significance of PIK3CA mutations in HR+/HER2- metastatic breast cancer and review the findings from two pivotal clinical trials, SOLAR-1 and CAPItello-291, which investigated the efficacy of targeted therapies in patients harboring these mutations.
EP: 1.Prevalence and Testing Strategies for ESR1
EP: 2.Evolution of Testing Strategies for ESR1
EP: 3.Dynamics of ESR1 Alterations and Serial Liquid Biopsies
EP: 4.Case Presentation 1: PIK3CA Mutation With ESR1 Mutations
EP: 5.EMERALD Study Design and Results for Elacestrant
EP: 6.Evolving Best Practices for ESR1 Testing
EP: 7.Case Presentation 2: Co-mutations in ESR1 and PIK3CA
Now Viewing
EP: 8.PIK3CA Mutations and Delivering PI3K Inhibitors
EP: 9.PostMONARCH: Dissecting Data on Sequential CDK 4/6 Inhibitors
EP: 10.Combinations and Treatment Sequence Strategies in Breast Cancer
EP: 11.Future Directions and Unmet Needs in HR+ Breast Cancer
EP: 12.Looking Ahead: Expert Future Perspectives in HR+ Breast Cancer
- Please also discuss findings from the SOLAR-1 and CAPI-tello-291 trials?
- How has the emergence of these targeted therapies impacted the treatment landscape?
- SOLAR-1 (Ciruelos et al. J. Clin Oncol. 2021)
- CAPI-tello-291 trials (NCTO4305496)
Related Videos
Related Content
